Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Proteasome Inhibition Suppresses The Induction Of Lipocalin-2 Upon Systemic Lipopolysaccharide Challenge In Mice.
  1. Home
  3. Proteasome Inhibition Suppresses The Induction Of Lipocalin-2 Upon Systemic Lipopolysaccharide Challenge In Mice.

Related Experiment Video

Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation
11:07

Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation

Published on: July 6, 2019

24.8K

Proteasome inhibition suppresses the induction of lipocalin-2 upon systemic lipopolysaccharide challenge in mice.

Jin-Sil Bae1, Ji-Eun Heo1, Kwon-Yul Ryu2

  • 1Department of Life Science, University of Seoul, 163 Seoulsiripdae-ro, Dongdaemun-gu, Seoul, 02504, Republic of Korea.

Molecular Brain
|October 4, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

The proteasome inhibitor bortezomib (BTZ) reduces harmful brain protein lipocalin-2 (Lcn2) levels in vivo. This finding suggests BTZ may alleviate neuroinflammation and neurotoxicity during systemic inflammation.

Keywords:
AstrocyteBortezomibLipocalin-2LipopolysaccharideNeuroinflammation

More Related Videos

Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach
08:24

Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach

Published on: May 2, 2018

19.4K
Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes
11:48

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes

Published on: May 31, 2018

11.4K

Related Experiment Videos

Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation
11:07

Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation

Published on: July 6, 2019

24.8K
Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach
08:24

Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach

Published on: May 2, 2018

19.4K
Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes
11:48

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes

Published on: May 31, 2018

11.4K

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Lipocalin-2 (Lcn2) is a detrimental protein implicated in neurodegeneration.
  • Reactive astrocytes secrete Lcn2, contributing to brain damage.
  • Previous in vitro studies showed bortezomib (BTZ) reduces Lcn2 in astrocytes.

Purpose of the Study:

  • To investigate if BTZ reduces Lcn2 levels in vivo.
  • To determine if BTZ mitigates neurotoxicity in lipopolysaccharide (LPS)-induced systemic inflammation.
  • To assess BTZ's effect on neuroinflammation markers.

Main Methods:

  • Mice were challenged with intraperitoneal injection of LPS.
  • LPS and BTZ were co-administered to assess their combined effects.
  • Brain tissue was analyzed for Lcn2 levels and glial marker gene expression.

Main Results:

  • LPS challenge significantly increased brain Lcn2 levels, consistent with in vitro findings.
  • Co-administration of LPS and BTZ markedly reduced Lcn2 levels compared to LPS alone.
  • BTZ co-administration hampered the LPS-induced upregulation of glial marker genes.

Conclusions:

  • Bortezomib (BTZ) effectively reduces lipocalin-2 (Lcn2) levels in the brain during LPS-induced inflammation in vivo.
  • BTZ shows potential in alleviating neuroinflammation and neurotoxicity associated with systemic inflammation.
  • These findings highlight BTZ as a potential therapeutic agent for inflammatory neurological conditions.